Clinical trials
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
Seen and heard: The Transmitter’s top multimedia stories in 2023
Our audio, video and photo highlights from the past year help to transport readers into scientists’ lives and research, and the lives of their study participants.
Seen and heard: The Transmitter’s top multimedia stories in 2023
Year in Review: Spectrum’s best in 2023
Here are five must-reads from our coverage of autism research over the past 12 months.
Standout neuroscience news in 2023
Did you miss any of our favorite stories from the past year? Revisit them here.
Unmasking Alzheimer’s disease
People with early-onset Alzheimer’s disease describe why they enrolled in clinical trials through the Dominantly Inherited Alzheimer Network (DIAN), in a new book of portrait photography.
New template streamlines sharing clinical trial results
This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.
New template streamlines sharing clinical trial results
Uncertainty and excitement surround one company’s cell therapy for epilepsy
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.
Uncertainty and excitement surround one company’s cell therapy for epilepsy
Trials test utility of EEG biomarkers for autism-related conditions
This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.
Trials test utility of EEG biomarkers for autism-related conditions
Is excess brain fluid an early marker of autism?
Brain scans of hundreds of infants suggest that up to 80 percent of those with autism have unusual amounts of cerebrospinal fluid. Researchers are studying how this might contribute to the condition.
Is excess brain fluid an early marker of autism?
Exclusive: Shake-up at top psychiatric institute following suicide in clinical trial
The New York State Psychiatric Institute in New York City is undergoing an audit and a change in leadership following a suicide that occurred during one of its clinical trials.
Exclusive: Shake-up at top psychiatric institute following suicide in clinical trial
Explore more from The Transmitter
Cocaine, morphine commandeer neurons normally activated by food, water in mice
Confirming a long-held hypothesis, repeated exposure to the drugs alters neurons in the nucleus accumbens, the brain’s reward center, and curbs an animal’s urge for sustenance.
Cocaine, morphine commandeer neurons normally activated by food, water in mice
Confirming a long-held hypothesis, repeated exposure to the drugs alters neurons in the nucleus accumbens, the brain’s reward center, and curbs an animal’s urge for sustenance.
X chromosome inactivation; motor difficulties in 16p11.2 duplication and deletion; oligodendroglia
Here is a roundup of autism-related news and research spotted around the web for the week of 6 May.
X chromosome inactivation; motor difficulties in 16p11.2 duplication and deletion; oligodendroglia
Here is a roundup of autism-related news and research spotted around the web for the week of 6 May.
Decoding flies’ motor control with acrobat-scientist Eugenia Chiappe
The tiny performers steal the show in Chiappe’s sensorimotor-integration lab in Lisbon, Portugal.
Decoding flies’ motor control with acrobat-scientist Eugenia Chiappe
The tiny performers steal the show in Chiappe’s sensorimotor-integration lab in Lisbon, Portugal.